Related Experiment Videos
Tandem transplantation in lymphoma
K P Papadopoulos1, W Noguera-Irizarry, C S Hesdorffer
1Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Bone Marrow Transplantation
|October 19, 2001
Summary
Conventional chemotherapy fails many poor-risk lymphoma patients. Advanced strategies like dose-intensification and tandem transplantation show promise for improving survival in these challenging cases.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Conventional chemotherapy is insufficient for many poor-risk lymphoma patients.
- Recurrent disease remains a significant cause of mortality in this population.
- Existing evidence suggests high-dose chemotherapy may offer superior outcomes.
Purpose of the Study:
- To explore advanced treatment strategies for poor-risk lymphoma.
- To evaluate the feasibility and tolerability of intensified chemotherapy regimens.
- To compare the potential efficacy of novel approaches against standard care.
Main Methods:
- Review of evidence for dose-intensification with high-dose chemotherapy and peripheral blood progenitor cell (PBPC) support.
- Analysis of tandem autologous high-dose chemotherapy (HDC) with PBPC support.
- Assessment of autologous followed by non-myeloablative allogeneic transplantation.
Main Results:
- Dose-intensification strategies, including tandem transplantation, are feasible and tolerable in poor-risk lymphoma.
- These aggressive approaches offer potential for improved survival.
- Further studies are needed to confirm superiority over current single high-dose therapy.
Conclusions:
- Aggressive treatment strategies are viable options for poor-risk lymphoma.
- Tandem transplantation warrants further investigation for selected patients.
- Optimizing survival in poor-risk lymphoma requires exploring intensified therapeutic approaches.